Last Week HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings

May 17, 2018 - By Don Salinas

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Corporate Logo

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

A total of 2 analysts rate HTG Molecular Diagnostics (NASDAQ:HTGM) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:HTGM) has 10 ratings reports on May 17, 2018 according to StockzIntelligence. On Wednesday, December 27 the stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) earned “Buy” rating by H.C. Wainwright. In Wednesday, January 24 report H.C. Wainwright maintained the stock with “Buy” rating. On Monday, January 8 the firm has “Buy” rating by Canaccord Genuity given. On Thursday, February 1 the stock has “Buy” rating by H.C. Wainwright. On Friday, January 5 H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating. H.C. Wainwright has “Buy” rating and $6.0 target. On Friday, March 23 the company was maintained by H.C. Wainwright. The stock rating was maintained by Canaccord Genuity with “Buy” on Friday, January 5. On Tuesday, May 8 H.C. Wainwright maintained the shares of HTGM in report with “Buy” rating. On Friday, March 23 the company was maintained by Canaccord Genuity. On Tuesday, April 17 the firm earned “Buy” rating by H.C. Wainwright. Listed here are HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) PTs and latest ratings.

08/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
17/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
23/03/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $7 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
27/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

The stock decreased 3.56% or $0.13 during the last trading session, hitting $3.52.HTG Molecular Diagnostics, Inc. has volume of 207,215 shares. Since May 17, 2017 HTGM has declined 59.58% and is downtrending. HTGM underperformed by 71.13% the S&P 500.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling.The company has $99.81 million market cap. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies.Currently it has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

For more HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news posted recently go to: Globenewswire.com, Globenewswire.com, Nasdaq.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “HTG Molecular Diagnostics Reports First Quarter 2018 Results” posted on May 10, 2018, “HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10” on April 27, 2018, “HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the …” with a publish date: May 10, 2018, “HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic …” and the last “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …” with publication date: May 02, 2018.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.